 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| |||||||||||||||||||||||||||||||||||||||||||||||||
Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.
SUMMARIES FOR PATIENTS
Hepatitis C Virus Infection in the United States, 1999 through 2002
16 May 2006 | Volume 144 Issue 10 | Page I-20
Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians.
The summary below is from the full report titled "The Prevalence of Hepatitis C Virus Infection in the United States, 1999 through 2002." It is in the 16 May 2006 issue of Annals of Internal Medicine (volume 144, pages 705-714). The authors are G.L. Armstrong, A. Wasley, E.P. Simard, G.M. McQuillan, W.L. Kuhnert, and M.J. Alter.
What is the problem and what is known about it so far?
Hepatitis C is the most common bloodborne infection in the United States. It is caused by the hepatitis C virus (HCV), which produces inflammation of the liver. New HCV infections can cause acute liver abnormalities, which resolve in some patients without treatment. In others, infection becomes chronic and may remain active for the rest of the person's life. Chronic HCV infection often causes no symptoms even though progressive liver damage is occurring. People chronically infected with HCV may develop liver failure, severe scarring of the liver (cirrhosis), or liver cancer. Currently, infection is most commonly transmitted by injection drug use. It can also be transmitted by having unprotected sex with an infected person. Before 1992 (when widespread screening of donated blood for infection began), the virus was also transmitted by transfusions. The Third National Health and Nutrition Examination Survey (NHANES III), a nationwide health survey performed from 1988 to 1994, indicated that about 3.9 million people (1.8% of the U.S. population) were infected with HCV.
Why did the researchers do this particular study?
To find out if, during the past decade, there had been any change in the characteristics of people being infected with HCV or in the patterns of infection in the United States.
Who was studied?
15,079 people who took part in a new NHANES survey from 1999 to 2002 and who provided blood samples for analysis.
How was the study done?
Participants were representative of the U.S. population. In addition to collecting information such as the participant's age, race, and ethnicity, the researchers collected blood samples and interviewed each participant to find out about sexual practices and illicit drug use. Blood samples were tested for evidence of past or present HCV infection.
What did the researchers find?
1.6% of the population had been infected with HCV, and about 80% of them had chronic active infection. Men had higher infection rates than women. Non-Hispanic black men between 40 and 49 years of age had the highest rate of infection. Infection rates were lower in participants younger than 40 years of age, and in this group there was no difference in likelihood of infection between black and white persons. The rate of infection was also lower in participants older than 49 years of age than in those 40 to 49 years of age. Infection was most strongly related to injection drug use in younger participants and to a history of blood transfusion before 1992 in older participants.
What are the limitations of the study?
Homeless people and people in jail were not included in the study even though these groups are known to have a high level of HCV infection.
What are the implications of the study?
Over the past decade, the overall rate of HCV infection has remained about the same. However, since Americans born between the late 1940s and the early 1960s have the highest rate of chronic infection, they are now reaching the age at which such complications as liver failure, cirrhosis, and liver cancer will become more prevalent.
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  Use of Enhanced Surveillance for Hepatitis C Virus Infection to Detect a Cluster Among Young Injection-Drug Users--New York, November 2004-April 2007 JAMA, July 2, 2008; 300(1): 34 - 36. [Full Text] [PDF]
|
|
|
|
 |
|
 M. F. McCown, S. Rajyaguru, S. Le Pogam, S. Ali, W.-R. Jiang, H. Kang, J. Symons, N. Cammack, and I. Najera The Hepatitis C Virus Replicon Presents a Higher Barrier to Resistance to Nucleoside Analogs than to Nonnucleoside Polymerase or Protease Inhibitors Antimicrob. Agents Chemother., May 1, 2008; 52(5): 1604 - 1612. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. H. Latka, H. Hagan, F. Kapadia, E. T. Golub, S. Bonner, J. V. Campbell, M. H. Coady, R. S. Garfein, M. Pu, D. L. Thomas, et al. A Randomized Intervention Trial to Reduce the Lending of Used Injection Equipment Among Injection Drug Users Infected With Hepatitis C Am J Public Health, May 1, 2008; 98(5): 853 - 861. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Ward Time for Renewed Commitment to Viral Hepatitis Prevention Am J Public Health, May 1, 2008; 98(5): 779 - 781. [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Guiltinan, Z. Kaidarova, B. Custer, J. Orland, A. Strollo, S. Cyrus, M. P. Busch, and E. L. Murphy Increased All-Cause, Liver, and Cardiac Mortality among Hepatitis C Virus-seropositive Blood Donors Am. J. Epidemiol., March 15, 2008; 167(6): 743 - 750. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Kaushik-Basu, A. Bopda-Waffo, T. T. Talele, A. Basu, P. R. R. Costa, A. J. M. da Silva, S. G. Sarafianos, and F. Noel Identification and characterization of coumestans as novel HCV NS5B polymerase inhibitors Nucleic Acids Res., March 1, 2008; 36(5): 1482 - 1496. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Page-Shafer, B. L. Pappalardo, L. H. Tobler, B. H. Phelps, B. R. Edlin, A. R. Moss, T. L. Wright, D. J. Wright, T. R. O'Brien, S. Caglioti, et al. Testing Strategy To Identify Cases of Acute Hepatitis C Virus (HCV) Infection and To Project HCV Incidence Rates J. Clin. Microbiol., February 1, 2008; 46(2): 499 - 506. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Morton, O. Landgren, N. Chatterjee, D. Castenson, R. Parsons, R. N. Hoover, and E. A. Engels Hepatitis C virus infection and risk of posttransplantation lymphoproliferative disorder among solid organ transplant recipients Blood, December 15, 2007; 110(13): 4599 - 4605. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. H. Silverman Viral Encounters with 2',5'-Oligoadenylate Synthetase and RNase L during the Interferon Antiviral Response J. Virol., December 1, 2007; 81(23): 12720 - 12729. [Full Text] [PDF]
|
|
|
|
|
|
T. Kanda, R. Steele, R. Ray, and R. B. Ray Hepatitis C Virus Infection Induces the Beta Interferon Signaling Pathway in Immortalized Human Hepatocytes J. Virol., November 15, 2007; 81(22): 12375 - 12381. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. G. Magalhaes, B. Greenberg, H. Hansen, and M. Glick Comorbidities in older patients with HIV: A retrospective study J Am Dent Assoc, November 1, 2007; 138(11): 1468 - 1475. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. L. Sedjo, T. Byers, E. Barrera Jr., C. Cohen, E. T. H. Fontham, L. A. Newman, C. D. Runowicz, A. G. Thorson, M. J. Thun, E. Ward, et al. A Midpoint Assessment of the American Cancer Society Challenge Goal to Decrease Cancer Incidence by 25% Between 1992 and 2015 CA Cancer J Clin, November 1, 2007; 57(6): 326 - 340. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Dimsdale and R. Dantzer A Biological Substrate for Somatoform Disorders: Importance of Pathophysiology Psychosom Med, November 1, 2007; 69(9): 850 - 854. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Donlin, N. A. Cannon, E. Yao, J. Li, A. Wahed, M. W. Taylor, S. H. Belle, A. M. Di Bisceglie, R. Aurora, J. E. Tavis, et al. Pretreatment Sequence Diversity Differences in the Full-Length Hepatitis C Virus Open Reading Frame Correlate with Early Response to Therapy J. Virol., August 1, 2007; 81(15): 8211 - 8224. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F J Basterra-Gortari and M Segui-Gomez Use of national health interview data to measure the burden of disease and injuries Inj. Prev., August 1, 2007; 13(4): 254 - 257. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. S. Dalrymple, T. Koepsell, J. Sampson, T. Louie, J. A. Dominitz, B. Young, and B. Kestenbaum Hepatitis C Virus Infection and the Prevalence of Renal Insufficiency Clin. J. Am. Soc. Nephrol., July 1, 2007; 2(4): 715 - 721. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. E. Alpers and J. Kowalewska Emerging Paradigms in the Renal Pathology of Viral Diseases Clin. J. Am. Soc. Nephrol., July 1, 2007; 2(Supplement_1): S6 - S12. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. I. Tsui, E. Vittinghoff, M. G. Shlipak, D. Bertenthal, J. Inadomi, R. A. Rodriguez, and A. M. O'Hare Association of Hepatitis C Seropositivity With Increased Risk for Developing End-stage Renal Disease Arch Intern Med, June 25, 2007; 167(12): 1271 - 1276. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. P. Giordano, L. Henderson, O. Landgren, E. Y. Chiao, J. R. Kramer, H. El-Serag, and E. A. Engels Risk of Non-Hodgkin Lymphoma and Lymphoproliferative Precursor Diseases in US Veterans With Hepatitis C Virus JAMA, May 9, 2007; 297(18): 2010 - 2017. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Wyles, K. A. Kaihara, F. Vaida, and R. T. Schooley Synergy of Small Molecular Inhibitors of Hepatitis C Virus Replication Directed at Multiple Viral Targets J. Virol., March 15, 2007; 81(6): 3005 - 3008. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Taylor and R. J. Fontana Hepatitis C in Organ Donors and Heart Transplant Recipients JAMA, February 21, 2007; 297(7): 696 - 696. [Full Text] [PDF]
|
|
|
|
|
|
G. L. Armstrong Injection Drug Users in the United States, 1979-2002: An Aging Population Arch Intern Med, January 22, 2007; 167(2): 166 - 173. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. H. Hoofnagle and L. B. Seeff Peginterferon and Ribavirin for Chronic Hepatitis C N. Engl. J. Med., December 7, 2006; 355(23): 2444 - 2451. [Full Text] [PDF]
|
|
|
|
|
|
P. R. Patel, A. K. Larson, A. D. Castel, L. M. Ganova-Raeva, R. A. Myers, B. J. Roup, K. P. Farrell, L. Edwards, O. Nainan, J. P. Krick, et al. Hepatitis C virus infections from a contaminated radiopharmaceutical used in myocardial perfusion studies. JAMA, October 25, 2006; 296(16): 2005 - 2011. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 HCV Infection in the U.S. Journal Watch (General), June 16, 2006; 2006(616): 4 - 4. [Full Text]
|
|
|
|
 |
|
 HCV Prevalence in the U.S. Journal Watch Gastroenterology, June 13, 2006; 2006(613): 10 - 10. [Full Text]
|
|
|
|
 |
|
 Prevalence of HCV Infection in the U.S. Journal Watch Infectious Diseases, June 9, 2006; 2006(609): 4 - 4. [Full Text]
|
|
|
|
 |
|
 A. Tonks What's new in the other general journals. BMJ, May 27, 2006; 332(7552): 1264 - 1265. [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Dienstag Hepatitis C: A Bitter Harvest Ann Intern Med, May 16, 2006; 144(10): 770 - 771. [Full Text] [PDF]
|
|
Read all Rapid Responses
| |||||||||||||||||||||||||||||||||||||||||||||||||
Article
